<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01405339</url>
  </required_header>
  <id_info>
    <org_study_id>PSMAD2011</org_study_id>
    <nct_id>NCT01405339</nct_id>
  </id_info>
  <brief_title>Budesonide Application Via Mucosal Atomization Device as a Treatment for Chronic Rhinosinusitis When Utilized as a Topical Nasal Steroid Spray</brief_title>
  <official_title>The Effect of Budesonide Spray Via Mucosal Atomization Device on the Hypothalamic-Pituitary Axis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Paul's Hospital, Canada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Paul's Hospital, Canada</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Budesonide, a steroid subtype, has been used as an adjunctive treatment for chronic
      rhinosinusitis as a topical nasal steroid spray. The current standard of care at St. Paul's
      Sinus Centre is to administer budesonide via the Mucosal Atomization Device (MAD). It is
      believed that the MAD is a better device than the standard nasal lavage because its fine mist
      enhances absorption and improves bioavailability. No studies have been done to determine if
      enhanced absorption and improved bioavailability of budesonide via MAD could potentially
      affect the hypothalamic-pituitary-adrenal (HPA) axis, resulting in the suppression of our own
      body's production of natural steroids.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cosyntropin testing and blood work for quantification of plasma budesonide and plasma cortisol.</measure>
    <time_frame>Participants will be followed for 30 days.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>SNOT-22 questionnaire to measure subjective perspective.</measure>
    <time_frame>Participants will be followed for the duration of post op standard of care, an expected average of 6 months.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Chronic Rhinosinusitis</condition>
  <arm_group>
    <arm_group_label>Budesonide via MAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The current standard of care at St. Paul's Sinus Centre is to administer budesonide via the Mucosal Atomization Device (MAD). Its believed that MAD is a better device than the standard nasal lavage (Budesonide diluted in saline and delivered via Nasal Irrigation Bottle)because its fine mist and higher concentration enhances absorption and improves bioavailability.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonide via Sinus Rinse Bottle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Budesonide via Sinus Rinse Bottle is the most commonly used delivery method.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mucosal Atomization Device (MAD)</intervention_name>
    <description>The use of pulmicort via MAD once a day for a total of 30 days.</description>
    <arm_group_label>Budesonide via MAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Budesonide via Nasal Syringe</intervention_name>
    <description>The use of budesonide via Sinus Irrigation Bottle will be once a day for 30 days.</description>
    <arm_group_label>Budesonide via Sinus Rinse Bottle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  19 years of age or older

          -  Diagnosed with CRS with or without polyps

          -  Awaiting for Functional Endoscopic Sinus Surgery

          -  Give consent on their own

        Exclusion Criteria:

        Concurrent or recent use (within the past 30 days) of systemic corticosteroids

          -  History of pituitary disease

          -  Morbid obesity (body mass index [calculated as weight in kilograms divided by height
             in meters squared]

          -  Concurrent or recent use of medications that accelerate the clearance of cortisol:

             o Such as dilantin, rifampin, amphetamines, or lithium carbonate

          -  Concurrent use of medications that interfere with the production of cortisol:

             o Such as ketoconazole, amphotericin B, bupropion, Echinacea, fluoroquinolones,
             itraconazole, licorice

          -  Use of oral contraception

          -  Use of female or male hormone therapy

          -  Known hypersensitivity to cortisol, corticotropin, or cosyntropin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amin R Javer, MD, FRCSC, FARS</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Paul's Hospital, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ENT Clinic, St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Lund VJ, Black JH, Szab√≥ LZ, Schrewelius C, Akerlund A. Efficacy and tolerability of budesonide aqueous nasal spray in chronic rhinosinusitis patients. Rhinology. 2004 Jun;42(2):57-62.</citation>
    <PMID>15224630</PMID>
  </reference>
  <reference>
    <citation>Sachanandani NS, Piccirillo JF, Kramper MA, Thawley SE, Vlahiotis A. The effect of nasally administered budesonide respules on adrenal cortex function in patients with chronic rhinosinusitis. Arch Otolaryngol Head Neck Surg. 2009 Mar;135(3):303-7. doi: 10.1001/archoto.2008.555.</citation>
    <PMID>19289711</PMID>
  </reference>
  <reference>
    <citation>Scott MB, Skoner DP. Short-term and long-term safety of budesonide inhalation suspension in infants and young children with persistent asthma. J Allergy Clin Immunol. 1999 Oct;104(4 Pt 2):200-9.</citation>
    <PMID>10518847</PMID>
  </reference>
  <reference>
    <citation>Bhalla RK, Payton K, Wright ED. Safety of budesonide in saline sinonasal irrigations in the management of chronic rhinosinusitis with polyposis: lack of significant adrenal suppression. J Otolaryngol Head Neck Surg. 2008 Dec;37(6):821-5.</citation>
    <PMID>19128710</PMID>
  </reference>
  <reference>
    <citation>Kanowitz SJ, Batra PS, Citardi MJ. Topical budesonide via mucosal atomization device in refractory postoperative chronic rhinosinusitis. Otolaryngol Head Neck Surg. 2008 Jul;139(1):131-6. doi: 10.1016/j.otohns.2008.03.009.</citation>
    <PMID>18585575</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2011</study_first_submitted>
  <study_first_submitted_qc>July 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2011</study_first_posted>
  <last_update_submitted>March 7, 2014</last_update_submitted>
  <last_update_submitted_qc>March 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Paul's Hospital, Canada</investigator_affiliation>
    <investigator_full_name>Amin Javer</investigator_full_name>
    <investigator_title>MD FRCSC FARS, Principal Investigator, Director of St Paul's Sinus Centre</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

